MedTrace Logo

Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

NCT03416543 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2021-12-23

No results posted yet for this study

Summary

First, this study will evaluate, in vitro, the cellular composition of the synovial fluid from patient with rheumatoid arthritis, gout or osteoarthritis.

Then samples will be test with a new format of bispecific antibody targeting dendritic cells. The production of IL-10 will be the principal criteria of judgment. Production of others cytokines like IL-1B, IL-6, IL-12 and IFN will be checked as well.

Conditions

Interventions

OTHER

Puncture

Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Denis MULLEMAN, MD-PhD · University Hospital, Tours

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-13
Primary Completion
2021-12-08
Completion
2021-12-08

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03416543 on ClinicalTrials.gov